Ulcerative Colitis
VIDEO: AI cannot replace GI physicians, but ‘with supervision’ may enhance IBD care
In a Healio video exclusive, Edward V. Loftus Jr., MD, acknowledged that although artificial intelligence has potential to radically change the way gastroenterologists practice medicine, “it’s not going to replace you.”
FDA gains steam in 2023: GI pipeline boasts numerous milestones, 2 crucial setbacks
The first half of 2023 has already seen landmark FDA decisions in the gastroenterology space, including multiple first-in-class therapies along with two costly rejections that highlight persistent gaps in the GI drug armory.
Amgen, J&J settle ustekinumab patent lawsuit in potential biosimilar market shake-up
Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing.
AI shows promise in diagnosis, treatment of IBD, but limitations, concerns remain
Artificial intelligence has been used in various ways to benefit patients with inflammatory bowel disease, with one of the main applications being the prediction and diagnosis of disease.
Immunomodulators heighten risk for high-grade cervical neoplasia, cancer in women with IBD
Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.
Digestive Disease Week roundup: Colorectal cancer data dominated; what else did you miss?
Digestive Disease Week 2023 in Chicago may have ended in early May, but Healio coverage has continued all month long. Wondering what you missed and what is coming next? Healio recaps the biggest meeting news making waves in the specialty.
FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar
The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.
FDA approves autoinjector option for upcoming adalimumab biosimilar
The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.
Frequent antibiotic use, diet rich in sweets, urban living heighten risk for pediatric IBD
CHICAGO — A diet rich in sweetened candy or drinks, exposure to antibiotics during early childhood and urban living were among risk factors for developing pediatric inflammatory bowel disease, according to data at Digestive Disease Week.
VIDEO: No change in concomitant medications after Rebyota for recurrent C. difficile, IBD
CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.